AR047536A1 - Moduladores del receptor de quimioquina ccr5 - Google Patents
Moduladores del receptor de quimioquina ccr5Info
- Publication number
- AR047536A1 AR047536A1 ARP050100437A ARP050100437A AR047536A1 AR 047536 A1 AR047536 A1 AR 047536A1 AR P050100437 A ARP050100437 A AR P050100437A AR P050100437 A ARP050100437 A AR P050100437A AR 047536 A1 AR047536 A1 AR 047536A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- cycloalkyl
- independently
- Prior art date
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- -1 NR5aR6a Chemical group 0.000 abstract 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004001 thioalkyl group Chemical group 0.000 abstract 3
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 1
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 1
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000001118 alkylidene group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005879 dioxolanyl group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
utiles en el tratamiento de una variedad de trastornos, incluyendo aquellos en que la modulacion de los receptores CCR5 está implicada. Los trastornos que se pueden tratar o prevenir mediante los presentes derivados incluyen VIH e infecciones retrovirales genéticamente relacionadas (y el resultante síndrome de inmunodeficiencia adquirida, SIDA), enfermedades del sistema inmune y enfermedades inflamatorias. Reivindicacion 1: Un compuesto de acuerdo con la formula (1), en donde: R2 es un grupo de formulas (2), A es (CH2)q; R1 es C(=O)R4, S(O)pR4, o C(=O)X, en donde X es NR5R6 o OR11; R2a y R2b son a) independientemente hidrogeno, C1-10 alquilo, C2-10 alquenilo, C1-10 haloalquilo, C3-7 cicloalquilo, (C3-7)cicloalquil-(C1-3)alquilo, C1-10 heteroalquilo, C1-10 alquilideno, C1-10 heteroalquilideno, arilo, aril-(C1-3)alquilo, heteroarilo, heteroaril-(C1-3)alquilo, C1-10 alquilo en donde 2 o 3 átomos de carbono no adyacentes son reemplazados independientemente con -O-, -S-, -NH- o - (CH2)wR8 en donde w es un numero entero de 2 a 6, y la cadena C2-6 alquileno opcionalmente contiene un doble enlace, -(CH2)wCH=NR9 en donde w es un numero entero de 2 a 6; o b) junto con los átomos de carbono a los que están unidos, son o-fenileno opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados del grupo consistente de C1-6 alquilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 tioalquilo, C1-6 alquilsulfonilo, halogeno, NR5aR6a, ciano y nitro con la condicion que si R2a, R2b, junto con los átomos de carbono a los que están unidos son o-fenileno opcionalmente sustituido, m es 1; R3 es C1-10 alquilo, C2-10 alquenilo, C1-10 heteroalquilo, C3-7 cicloalquilo, C1-6 alquilheterociclo, arilo, aril-(C1-3)alquilo, heteroarilo, C1-6 alquil heteroarilo, C(=O)R3a en donde R3a es C1-10 alquilo, C2-10 alquenilo o C3-7 cicloalquilo, o un fragmento de grupo de formulas (3), R4 es C1-10 alquilo, C3-7 cicloalquil-(C1-10)alquilo sustituido, heterociclo, arilo, o heteroarilo; R5 y R6 son a) H, C1-10 alquilo, C1-10 heteroalquilo, C3-7 cicloalquilo, (C1-6)alquil-(C3-7)cicloalquilo, heterociclo-(C1-6)alquilo, arilo, aril-(C1-3)alquilo, heteroarilo, C1-6 alquil heteroarilo cuando se cogen independientemente; o b) C3-6 alquileno o [(CH2)]2O cuando son cogidos juntos; R5a y R6a son a) hidrogeno, C1-6 alquilo o C1-6 alquilcarbonilo cuando se cogen independientemente o b) C3-6 alquileno o [(CH2)]2O cuando se cogen juntos; R7 es hidrogeno, ciano o C1-6 alquilo; R8 es -CN, -NO2, -CONR5aR6a, COR9, -NHSO2(C1-6)alquilo; R9 es OH o C1-6 alcoxilo; R10 es N o N+-O-; R11 es C1-10 alquilo, C1-10 heteroalquilo, C3-7 cicloalquilo, (C1-6)alquil-(C3-7)cicloalquil, heterociclo-(C1-6)alquilo, arilo, aril-(C1- 3)alquilo, heteroarilo (C1-6)alquil-heteroarilo; m es 0 o 1; n es independientemente 0 a 2; o es independientemente 0 o 1; p es 0 a 2; q es 1 a 3; en donde: cada dicho heteroarilo se selecciona independientemente del grupo consistente de piridilo, 1- oxi-piridinilo, pirimidilo, oxipirimidinilo, pirazinilo, piridazinilo, pirrolilo, tienilo, furilo, imidazolilo, pirazolilo, oxazolilo, tiazolilo, isoxazolilo, isotiazolilo, indolinilo, N-Boc-indolinilo, quinolinilo, isoquinoli-nilo, benzofuranilo, 4,5,6,7-tetrahidrobenzofuranilo y 1,2,3,4-tetrahidroacridinilo; cada dicho arilo y dicho heteroarilo están opcionalmente independientemente sustituidos con 1 a 3 sustituyentes seleccionados del grupo consistente de hidroxilo, C1-6 alquilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 haloalcoxilo, C1-6 tioalquilo, arilo, aril-(C1-3)alquilo, ariloxilo, heteroariloxilo, tioarilo, tioheteroarilo, aril-(C1-3)alcoxilo, heteroarilo, heterociclilo, C1-6 alquilheterociclo, C1-6 alquilsulfonilo, -NHSO2(C1- 6)alquilo, SO2NR5aR6a, (CH2)uCO2R9, (CH2)uCONR5aR6a, -X1C(=O)X2, C1-10 alquilcarbonilo, halogeno, NR5aR6a, ciano, nitro y C1-10 alquilo en donde 2 o 3 átomos de carbono no adyacentes son reemplazados independientemente con -O-, -S-, -NH- o NR5, en donde u es un numero entero de 0 a 6, X1 es NR6b o O; X2 es NR5R6 o OR3 y R5b es H o C1-6 alquilo; cada dicho heterociclo se selecciona independientemente del grupo consistente de pirrolidinilo, 1-metil-pirrolidinilo, piperidinilo, morfolinilo, tiomorfolinilo, tetrahidrofuranilo, dioxolanilo y piranilo opcionalmente sustituido con 1 a 3 sustituyentes independientemente seleccionados del grupo consistente de hidroxi-(C1-6)alquilo, C1-6 haloalquilo, C1-6 alcoxilo, C1-6 tioalquilo, C1-6 alquilsulfonilo, halogeno, NR5R6a, ciano y nitro; enantiomeros puros, enantiomeros parcialmente resueltos, mezclas racémicas, sales de adicion ácida farmacéuticamente aceptables, hidratos y solvatos de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54340804P | 2004-02-10 | 2004-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047536A1 true AR047536A1 (es) | 2006-01-25 |
Family
ID=34837578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100437A AR047536A1 (es) | 2004-02-10 | 2005-02-08 | Moduladores del receptor de quimioquina ccr5 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7332500B2 (es) |
| EP (1) | EP1716156A2 (es) |
| JP (1) | JP2007522160A (es) |
| KR (1) | KR100863854B1 (es) |
| CN (1) | CN100497346C (es) |
| AR (1) | AR047536A1 (es) |
| AU (1) | AU2005211499A1 (es) |
| BR (1) | BRPI0507586A (es) |
| CA (1) | CA2554671A1 (es) |
| CO (1) | CO5700742A2 (es) |
| IL (1) | IL176720A0 (es) |
| NO (1) | NO20063495L (es) |
| RU (1) | RU2006132465A (es) |
| TW (1) | TW200529857A (es) |
| WO (1) | WO2005075484A2 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6374762B1 (en) * | 1997-10-27 | 2002-04-23 | Correct Craft, Inc. | Water sport towing apparatus |
| WO2006023852A2 (en) * | 2004-08-19 | 2006-03-02 | Vertex Pharmaceuticals, Incorporated | Modulators of muscarinic receptors |
| US7786141B2 (en) * | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| JP2008521825A (ja) * | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| ATE469159T1 (de) * | 2005-03-03 | 2010-06-15 | Janssen Pharmaceutica Nv | Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten |
| ES2350647T3 (es) | 2005-03-08 | 2011-01-25 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1). |
| AU2006303368B2 (en) | 2005-10-19 | 2011-05-26 | F. Hoffmann-La Roche Ag | Non-Nucleoside Reverse Transcriptase Inhibitors |
| CN101374519A (zh) * | 2005-12-22 | 2009-02-25 | 弗特克斯药品有限公司 | 毒蕈碱性受体调节剂 |
| CA2642649A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| CN101426499A (zh) | 2006-02-22 | 2009-05-06 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| CN101500565A (zh) * | 2006-06-29 | 2009-08-05 | 弗特克斯药品有限公司 | 毒蕈碱性受体的调节剂 |
| CN101553231A (zh) * | 2006-08-15 | 2009-10-07 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| CN101501002B (zh) | 2006-08-16 | 2012-06-27 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
| EP2051715A2 (en) | 2006-08-18 | 2009-04-29 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
| ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
| EP2128163A1 (en) * | 2007-01-25 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Spiro-ring compound |
| AU2008233930A1 (en) * | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US7977358B2 (en) * | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
| WO2009037168A1 (en) * | 2007-09-19 | 2009-03-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2700724A1 (en) * | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2009135788A1 (en) * | 2008-05-09 | 2009-11-12 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2764759A1 (en) | 2009-06-09 | 2010-12-16 | Defyrus, Inc. | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
| EP2721025B1 (en) * | 2011-06-16 | 2015-11-25 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| IN2014KN01075A (es) | 2011-11-18 | 2015-10-09 | Heptares Therapeutics Ltd | |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| SG11201803153RA (en) * | 2015-11-16 | 2018-06-28 | Esteve Labor Dr | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| US20220233512A1 (en) * | 2020-11-03 | 2022-07-28 | Cassava Sciences, Inc. | Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL127065C (es) * | 1964-04-22 | |||
| HU204529B (en) * | 1989-08-10 | 1992-01-28 | Richter Gedeon Vegyeszet | Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them |
| HU204054B (en) * | 1989-08-10 | 1991-11-28 | Richter Gedeon Vegyeszet | Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same |
| NZ320963A (en) | 1995-09-29 | 1999-08-30 | Lilly Co Eli | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| CZ20013940A3 (cs) * | 1999-05-04 | 2002-04-17 | Schering Corporation | Piperazinové deriváty uľitečné jako CCR5 antagonisté |
| US6689765B2 (en) * | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| EP1659111A3 (en) | 1999-05-04 | 2007-05-09 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| TWI224597B (en) | 1999-12-03 | 2004-12-01 | Ono Pharmaceutical Co | Triazaspiro[5.5]undecane derivatives and a medicine containing the derivatives as an active ingredient |
| AU2001230537A1 (en) | 2000-02-01 | 2001-08-14 | Daiichi Pharmaceutical Co., Ltd. | Pyridoxazine derivatives |
| WO2001064213A1 (en) * | 2000-03-02 | 2001-09-07 | Smithkline Beecham Corporation | Compounds and methods |
| BR0209604A (pt) * | 2001-05-14 | 2004-03-23 | Hoffmann La Roche | Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina |
| CN101050215A (zh) | 2001-12-28 | 2007-10-10 | 阿卡蒂亚药品公司 | 作为单胺受体调节剂的螺氮杂环化合物 |
-
2005
- 2005-02-01 RU RU2006132465/04A patent/RU2006132465A/ru not_active Application Discontinuation
- 2005-02-01 AU AU2005211499A patent/AU2005211499A1/en not_active Abandoned
- 2005-02-01 CA CA002554671A patent/CA2554671A1/en not_active Abandoned
- 2005-02-01 BR BRPI0507586-6A patent/BRPI0507586A/pt not_active IP Right Cessation
- 2005-02-01 JP JP2006552503A patent/JP2007522160A/ja active Pending
- 2005-02-01 WO PCT/EP2005/000976 patent/WO2005075484A2/en not_active Ceased
- 2005-02-01 KR KR1020067016037A patent/KR100863854B1/ko not_active Expired - Fee Related
- 2005-02-01 CN CNB2005800045181A patent/CN100497346C/zh not_active Expired - Fee Related
- 2005-02-01 EP EP05707116A patent/EP1716156A2/en not_active Withdrawn
- 2005-02-05 TW TW094103869A patent/TW200529857A/zh unknown
- 2005-02-08 AR ARP050100437A patent/AR047536A1/es unknown
- 2005-02-10 US US11/055,642 patent/US7332500B2/en not_active Expired - Fee Related
-
2006
- 2006-07-05 IL IL176720A patent/IL176720A0/en unknown
- 2006-07-31 NO NO20063495A patent/NO20063495L/no not_active Application Discontinuation
- 2006-07-31 CO CO06074877A patent/CO5700742A2/es not_active Application Discontinuation
-
2008
- 2008-01-11 US US12/008,452 patent/US7538122B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060108770A (ko) | 2006-10-18 |
| EP1716156A2 (en) | 2006-11-02 |
| US20050176703A1 (en) | 2005-08-11 |
| WO2005075484A3 (en) | 2005-10-20 |
| WO2005075484A2 (en) | 2005-08-18 |
| NO20063495L (no) | 2006-11-01 |
| JP2007522160A (ja) | 2007-08-09 |
| CN1918171A (zh) | 2007-02-21 |
| AU2005211499A1 (en) | 2005-08-18 |
| IL176720A0 (en) | 2006-10-31 |
| US20080139544A1 (en) | 2008-06-12 |
| CA2554671A1 (en) | 2005-08-18 |
| KR100863854B1 (ko) | 2008-10-15 |
| US7538122B2 (en) | 2009-05-26 |
| CO5700742A2 (es) | 2006-11-30 |
| TW200529857A (en) | 2005-09-16 |
| RU2006132465A (ru) | 2008-03-20 |
| BRPI0507586A (pt) | 2007-07-03 |
| US7332500B2 (en) | 2008-02-19 |
| CN100497346C (zh) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047536A1 (es) | Moduladores del receptor de quimioquina ccr5 | |
| ZA202301437B (en) | Compounds and methods for treatment of viral infections | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| RU2018121499A (ru) | Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1 | |
| AR047063A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide | |
| AR070361A1 (es) | Compuestos heterociclicos antiviricos | |
| EA200701850A1 (ru) | Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| PE20080998A1 (es) | Derivados de pirazol como inhibidores del sistema enzimatico cyp450 | |
| PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| UY29177A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos | |
| EA200702493A1 (ru) | Соединения и способы лечения или предотвращения флавивирусных инфекций | |
| PE20081658A1 (es) | Derivados indolicos con anillo unido en las posiciones 5,6 y sus metodos de uso | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR035665A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| CY1111871T1 (el) | Υποκατεστημενα βενζιμιδαζολια και μεθοδοι παρασκευης | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| NO20072235L (no) | HCV-hemmende bicykliske pyrimidiner | |
| ECSP088324A (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
| NO20070336L (no) | Indolderivater som histamin-reseptorantagonister | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| NO20080392L (no) | Pyrazolpyridinderivater som inhibitorer av beta-adrenergisk receptorkinase 1 | |
| CL2019001455A1 (es) | Productos combinados para el tratamiento del vsr (divisional de la solicitud n°1808-2018). | |
| PE20220252A1 (es) | Compuestos de pirrol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |